Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | KEYNOTE-048: progression post next line for R/M HNSCC

Barbara Burtness, MD, Yale Cancer Center, New Haven, CT, USA, discusses data from the KEYNOTE-048 study (NCT02358031) which evaluated progression after the next line of therapy following pembrolizumab or pembrolizumab plus chemotherapy vs the EXTREME regimen as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.